Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database
Abstract
OBJECTIVES: The increasing use of tumor necrosis factor (TNF) inhibitors poses new challenges in terms of drug iatrogenicity and diagnosis. In this study, we focus on the description of the TNF-inhibitors-induced vasculitis. METHODS: We conducted a retrospective descriptive study using the French national pharmacovigilance database to study cases of vasculitis attributable to TNF-inhibitor treatment. RESULTS: A total of 164 cases were analyzed, patients' mean age was 49.1 years, and 61.4% were women. The indications for TNF-inhibitor therapy were Crohn's disease (27%), rheumatoid arthritis (27%) and ankylosing spondylitis (21%). The median time to onset of vasculitis was 390 days [120-1095]. Clinical manifestations included cutaneous manifestations (88%), mainly purpura, rheumatic manifestations (27%), general symptoms (15%), renal manifestations (14%) and gastrointestinal and neurological manifestations (8% each). Skin biopsy was the most important diagnostic test, with 67.7% of cases showing vasculitis. Our study found mainly nonspecific vasculitis (54.9%), IgA vasculitis (28%) and ANCA vasculitis (7.9%). A possible association was observed between IgA vasculitis and TNF-inhibitors treatment for Crohn's disease, compared with other indications. CONCLUSION: Our study, based on national pharmacovigilance data, provides a better characterization of TNF-inhibitor-induced vasculitis. Resolution of vasculitis upon TNF inhibitor discontinuation, followed by recurrence upon reintroduction, confirms the drug's causative role and suggests that treatment should be stopped if possible. Clinicians should exercise heightened vigilance for symptom onset within the first 500 days of therapy. The atypical features of certain vasculitis, particularly from an epidemiological perspective given the unusual age at presentation, should prompt consideration of an iatrogenic etiology, including potential anti-TNF involvement.
Related
- Adverse effects of gender‐affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database
- Win ratio analysis of surgical approaches for lung cancer: a nationwide observational study using the French national hospital discharge database
- Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
- Adherence to French guidelines on cuff leak test use across French intensive care units: a national survey
- Surgical management of urolithiasis in france from 2016 to 2022: epidemiological data from the national PMSI database
BibTeX
@article{izquierdo2026antitnfinduced,
title = {{Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database}},
author = {Facundo Izquierdo and Greta Gourier and Caroline Clabecq and Elliot Ewig and Florelle Bellet and Romain Barus and Pauline-Eva Pecquet and Bénédicte Rouvière},
journal = {Postgraduate Medicine},
year = {2026},
month = jul,
doi = {10.1080/00325481.2026.2696097},
url = {https://hal.science/hal-05837515v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database
AU - Facundo Izquierdo
AU - Greta Gourier
AU - Caroline Clabecq
AU - Elliot Ewig
AU - Florelle Bellet
AU - Romain Barus
AU - Pauline-Eva Pecquet
AU - Bénédicte Rouvière
PY - 2026
DA - 2026/07/05
JO - Postgraduate Medicine
DO - 10.1080/00325481.2026.2696097
UR - https://hal.science/hal-05837515v1
AB - OBJECTIVES: The increasing use of tumor necrosis factor (TNF) inhibitors poses new challenges in terms of drug iatrogenicity and diagnosis. In this study, we focus on the description of the TNF-inhibitors-induced vasculitis. METHODS: We conducted a retrospective descriptive study using the French national pharmacovigilance database to study cases of vasculitis attributable to TNF-inhibitor treatment. RESULTS: A total of 164 cases were analyzed, patients' mean age was 49.1 years, and 61.4% were women. The indications for TNF-inhibitor therapy were Crohn's disease (27%), rheumatoid arthritis (27%) and ankylosing spondylitis (21%). The median time to onset of vasculitis was 390 days [120-1095]. Clinical manifestations included cutaneous manifestations (88%), mainly purpura, rheumatic manifestations (27%), general symptoms (15%), renal manifestations (14%) and gastrointestinal and neurological manifestations (8% each). Skin biopsy was the most important diagnostic test, with 67.7% of cases showing vasculitis. Our study found mainly nonspecific vasculitis (54.9%), IgA vasculitis (28%) and ANCA vasculitis (7.9%). A possible association was observed between IgA vasculitis and TNF-inhibitors treatment for Crohn's disease, compared with other indications. CONCLUSION: Our study, based on national pharmacovigilance data, provides a better characterization of TNF-inhibitor-induced vasculitis. Resolution of vasculitis upon TNF inhibitor discontinuation, followed by recurrence upon reintroduction, confirms the drug's causative role and suggests that treatment should be stopped if possible. Clinicians should exercise heightened vigilance for symptom onset within the first 500 days of therapy. The atypical features of certain vasculitis, particularly from an epidemiological perspective given the unusual age at presentation, should prompt consideration of an iatrogenic etiology, including potential anti-TNF involvement.
SN - 0032-5481
ER -